Alzheimer's Research & Therapy

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
		Commentary Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease Suzanne B Hendrix, Kathleen A Welsh-Bohmer Alzheimer's Research & Therapy 2013, 5:22 (15 May 2013) Abstract \| Full text \| PDF
		Research The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, Dave Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013) Abstract \| Provisional PDF \| PubMed \| Editor’s summary Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
		Review Advances in blood-based protein biomarkers for Alzheimer's disease Lorraine Clark, Thomas Kodadek Alzheimer's Research & Therapy 2013, 5:18 (9 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.
		Review Modeling Alzheimer's disease with non-transgenic rat models Laurent Lecanu, Vassilios Papadopoulos Alzheimer's Research & Therapy 2013, 5:17 (1 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.
		Review Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker, Allan I Levey Alzheimer's Research & Therapy 2013, 5:21 (29 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.
		Review 5-HT₆receptors and Alzheimer's disease María Ramírez Alzheimer's Research & Therapy 2013, 5:15 (22 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT₆ receptor compounds, resulting in 5-HT₆-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).
		Research Neuroprotective effects of D-Ala²GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model Emilie Faivre, Christian Hölscher Alzheimer's Research & Therapy 2013, 5:20 (19 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.
		Research Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models Robyn M Loureiro, Jo Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk, Barbara Tate Alzheimer's Research & Therapy 2013, 5:19 (18 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.
		Review DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease Jyotshna Kanungo Alzheimer's Research & Therapy 2013, 5:13 (8 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jyotshna Kanungo discusses possible mechanisms for the role of DNA-dependent protein kinase (DNA-PK) in neurodegeneration leading to Alzheimer's disease.
		Letter Plasma tau levels in Alzheimer's disease Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansson Alzheimer's Research & Therapy 2013, 5:9 (28 March 2013) Abstract \| Full text \| PDF \| PubMed
		Research The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection Wolfgang W Quitschke, Nicole Steinhauff, Jean Rooney Alzheimer's Research & Therapy 2013, 5:16 (28 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Biweekly intravenous curcuminoid injections at high concentration reduced the plaque load in transgenic Alzheimer's mice to 70% of the control value, but are rapidly metabolised to undetectable levels within 20 minutes.
		Debate Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease? Harald Hampel, Simone Lista Alzheimer's Research & Therapy 2013, 5:11 (18 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Have we learnt all we need to know from genetic studies in Alzheimer's disease (AD)? Harald Hampel and Simone Lista argue that genetics is not over in AD research, in fact it is more at the beginning than at the end.
		Review Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Jon B Toledo, Leslie M Shaw, John Q Trojanowski Alzheimer's Research & Therapy 2013, 5:8 (8 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Toledo, Shaw and Trojanowski review cross-sectional and longitudinal studies of plasma Aβ as a blood-based biomarker for Alzheimer's disease (AD), discussing its potential as a cost effective and non-invasive diagnostic tool.
		Review Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems Douglas Galasko, Todd E Golde Alzheimer's Research & Therapy 2013, 5:10 (7 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Editors-in-Chief Douglas Galasko and Todd Golde introduce a new special series on Peripheral Biomarkers by providing an overview of key concepts relating to Alzheimer’s disease (AD) plasma, serum and blood biomarker studies.
		Research Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth, Alan J Lerner, The Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2013, 5:14 (6 March 2013) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Conversion rates of mild cognitive impairment patients at high risk for progression to Alzheimer's disease (AD) were identified using a novel statistical method based on partially ordered set (poset) models.
		Research Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell, Randi Fain Alzheimer's Research & Therapy 2013, 5:12 (21 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Donepezil 23 mg/day provides significant benefits over 10 mg/day across a range of cognitive domains in patients with moderate to severe Alzheimer's disease, especially in the language domain.
		Editorial The C9ORF72 mutation brings more answers and more questions Bruce L Miller Alzheimer's Research & Therapy 2013, 5:7 (18 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Bruce Miller, Guest Editor of the special series: The new FTD mutation on chromosome 9, discusses the C9ORF72 mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.
		Meeting report Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery Rachel F Lane, Penny A Dacks, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2013, 5:5 (4 February 2013) Abstract \| Full text \| PDF \| PubMed
		Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
		Research Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
		Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
		Review Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss, Sandra E Black Alzheimer's Research & Therapy 2013, 5:1 (9 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lam and colleagues review the different subtypes of Alzheimer's disease (AD), discussing the need for personalized AD medicine and the potential for targeting specific AD subtypes in future clinical trials.
		Research Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application Carina Wattmo, Erik Jedenius, Kaj Blennow, Åsa K Wallin Alzheimer's Research & Therapy 2013, 5:2 (3 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary High compliance to treatment with cholinesterase inhibitor galantamine was seen in a clinical study of patients with Alzheimer's disease (AD), with plasma concentration correlating strongly to dosage.
		Commentary Assessment of psychiatric changes in C9ORF72 frontotemporal dementia Michael Hornberger Alzheimer's Research & Therapy 2012, 4:49 (24 December 2012) Abstract \| Full text \| PDF \| PubMed
		Review Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? Amanda N Sacino, Benoit I Giasson Alzheimer's Research & Therapy 2012, 4:48 (17 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Sacino and Giasson review evidence that a self-promoting prion-like mechanism may contribute to the spread and progression of alpha-synuclein pathology in Parkinson’s disease and other synucleinopathies, calling for further study.
		Research Plasma lipoprotein-associated phospholipase A₂activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study Julie E Davidson, Andrew Lockhart, Leslie Amos, Heide A Stirnadel-Farrant, Vincent Mooser, Marc Sollberger, Axel Regeniter, Andreas U Monsch, Michael C Irizarry Alzheimer's Research & Therapy 2012, 4:51 (7 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Levels of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) did not correlate with cerebrospinal fluid biomarkers such as Abeta and Tau in Alzheimer's disease patients in a cross-sectional study.
		Review NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease Walter J Lukiw Alzheimer's Research & Therapy 2012, 4:47 (6 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Walter Lukiw reviews how epigenetic factors, including NF-kappaB-regulated proinflammatory miRNAs, show an increased abundance in Alzheimer disease (AD) brains and discusses the potential therapeutic applications of miRNA inhibitors.
		Review Treatment implications of C9ORF72 Sharon J Sha, Adam Boxer Alzheimer's Research & Therapy 2012, 4:46 (27 November 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Sha and Boxer discuss the animal models and research tools needed to understand the clinical phenotypes of frontotemporal dementia and amyotrophic lateral sclerosis linked to chromosome 9 (c9FTD/ALS) in C9ORF72-mediated disease.
		Research Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action Patrick D Roberts, Athan Spiros, Hugo Geerts Alzheimer's Research & Therapy 2012, 4:50 (26 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Computational analysis of the pathology and mechanisms of drug action in Alzheimer's disease may improve clinical success rates by addressing the translational gap between preclinical animal models and clinical outcomes.
		Review Neuroimaging features of C9ORF72 expansion Jennifer S Yokoyama, Howard J Rosen Alzheimer's Research & Therapy 2012, 4:45 (16 November 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Yokoyama and Rosen review neuroimaging studies on the pathogenic C9ORF72 expansion; establishing that unique characteristics of C9ORF72-associated disease may aid identification of patients for genetic screening and diagnosis.
		Review Stem cell models of Alzheimer's disease and related neurological disorders Frederick J Livesey Alzheimer's Research & Therapy 2012, 4:44 (6 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Frederick Livesey reviews the feasibility of neuronal stem cell models in Alzheimer's disease (AD), discussing the progress in using this approach to generate useful human models of AD and its future potential.
		Research Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study John M Ringman, Sally A Frautschy, Edmond Teng, Aynun N Begum, Jenny Bardens, Maryam Beigi, Karen H Gylys, Vladimir Badmaev, Dennis D Heath, Liana G Apostolova, Verna Porter, Zeba Vanek, Gad A Marshall, Gerhard Hellemann, Catherine Sugar, Donna L Masterman, Thomas J Montine, Jeffrey L Cummings, Greg M Cole Alzheimer's Research & Therapy 2012, 4:43 (29 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Oral curcumin did not lead to changes in cognitive examinations or plasma biomarker levels in a 24-week randomized, double blind, placebo-controlled study in patients with Alzheimer disease (AD).
		Review Potential sources of interference on Abeta immunoassays in biological samples Hugo Vanderstichele, Erik Stoops, Eugeen Vanmechelen, Andreas Jeromin Alzheimer's Research & Therapy 2012, 4:39 (17 October 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Vanderstichele and colleagues review the importance of assay interferences when diagnosing and measuring therapy responses in Alzheimer's disease (AD); discussing how to make assays more acceptable as in vitro diagnostic biomarker tests.
		Review Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease Leonel T Takada, Sharon J Sha Alzheimer's Research & Therapy 2012, 4:38 (3 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Takada and Sha review the neuropsychiatric features of chromosome 9p-linked frontotemporal dementia (FTD) and the risk that some C9orf72 mutation carriers may be misdiagnosed with primary psychiatric conditions.
		Commentary C9orf72 immunohistochemistry in Alzheimer's disease Tibor Hortobágyi Alzheimer's Research & Therapy 2012, 4:37 (26 September 2012) Abstract \| Full text \| PDF \| PubMed
		Research Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions Colin J Mahoney, Laura E Downey, Gerard R Ridgway, Jon Beck, Shona Clegg, Melanie Blair, Sarah Finnegan, Kelvin K Leung, Tom Yeatman, Hannah Golden, Simon Mead, Jonathan D Rohrer, Nick C Fox, Jason D Warren Alzheimer's Research & Therapy 2012, 4:41 (24 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Longitudinal neuropsychological and neuroimaging data on a cohort of patients with pathological repeat expansions in C9ORF72 is assessed, demonstrating longitudinal biomarkers for tracking the evolution of the C9ORF72 mutation phenotype.
		Commentary Dementia: a global health priority - highlights from an ADI and World Health Organization report Marc Wortmann Alzheimer's Research & Therapy 2012, 4:40 (21 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Marc Wortmann, Executive Director of Alzheimer's Disease International, provides a special commentary explaining the importance of World Alzheimer Reports and the need to create national Alzheimer Plans to provide frameworks for action.
		Commentary Championing of dementia in England Zeinab Abdi, Alistair Burns Alzheimer's Research & Therapy 2012, 4:36 (11 September 2012) Abstract \| Full text \| PDF \| PubMed
		Review Alzheimer's disease diagnostic criteria: practical applications Jeffrey Cummings Alzheimer's Research & Therapy 2012, 4:35 (5 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jeffrey Cummings reviews the advantages and limitations of the IWG and NIA/AA Alzheimer's disease (AD) diagnostic criteria, and discusses improvements for future revisions.
		Review Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease Adam Kline Alzheimer's Research & Therapy 2012, 4:32 (27 August 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Adam Kline discusses therapeutic approaches targeting apolipoprotein E (apoE), the most significant risk factor for non-familial Alzheimer's disease (AD), including key interactions of apoE and amyloid-beta pathology and preclinical animal models.
		Research Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort Sheng Jin, Pau Pastor, Breanna Cooper, Sebastian Cervantes, Bruno A Benitez, Cristina Razquin, Alison Goate, Ibero-American Alzheimer Disease Genetics Group Researchers, Carlos Cruchaga Alzheimer's Research & Therapy 2012, 4:34 (20 August 2012) Abstract \| Full text \| PDF \| PubMed \| F1000 Biology \| Editor’s summary Pooled-DNA sequencing identifies novel GRN and MAPT mutations that match the frequency of APP, PSEN1 and PSEN2 mutations in clinical Alzheimer's disease (AD) cases, suggesting an influence on frontotemporal dementia and AD phenotypes.
		Research Dystrophic neurites express C9orf72 in Alzheimer's disease brains Jun-ichi Satoh, Hiroko Tabunoki, Tsuyoshi Ishida, Yuko Saito, Kunimasa Arima Alzheimer's Research & Therapy 2012, 4:33 (16 August 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary C9orf72 and UBQLN-1 expression in a cluster of dystrophic neurites in senile plaques in Alzheimer's disease brains suggests C9orf72 has a role in the process of neurodegeneration.
		Research Impaired self-other differentiation in frontotemporal dementia due to the C9ORF72 expansion Laura E Downey, Colin J Mahoney, Martin N Rossor, Sebastian J Crutch, Jason D Warren Alzheimer's Research & Therapy 2012, 4:42 (13 August 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
		Debate Con: Alzheimer's disease and circadian dysfunction: chicken or egg? Abhay Moghekar, Richard J O'Brien Alzheimer's Research & Therapy 2012, 4:26 (13 August 2012) Abstract \| Full text \| PDF \| PubMed
		Debate Pro: Alzheimer's disease and circadian dysfunction: chicken or egg? Tracy A Bedrosian, Randy J Nelson Alzheimer's Research & Therapy 2012, 4:25 (13 August 2012) Abstract \| Full text \| PDF \| PubMed
		Research Increased expression of the homologue of enhancer-of-split 1 protects neurons from beta amyloid neurotoxicity and hints at an alternative role for transforming growth factor beta1 as a neuroprotector Pedro J Chacón, Alfredo Rodríguez-Tébar Alzheimer's Research & Therapy 2012, 4:31 (31 July 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Up-regulating the gene Hes1 largely counteracted the effects of amyloid beta (Aβ) on neurons, maintaining GABAergic signaling and preventing cell death; providing strategies for limiting the effects of Alzheimer's disease.
		Review Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia Jennifer C Schymick, Bryan J Traynor Alzheimer's Research & Therapy 2012, 4:30 (26 July 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
		Review Cognitive and behavioral features of c9FTD/ALS Bradley F Boeve, Neill R Graff-Radford Alzheimer's Research & Therapy 2012, 4:29 (20 July 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Boeve and Graff-Radford review the major new findings in familial frontotemporal dementia and/or amyotrophic lateral sclerosis linked to chromosome 9 (c9FTD/ALS) and its recently discovered pathogenic C9ORF72 hexanucleotide expansion.
		Review Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion Jamie C Fong, Anna M Karydas, Jill S Goldman Alzheimer's Research & Therapy 2012, 4:27 (19 July 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Fong and colleagues discuss the genetic counselling considerations for individuals and their families considering genetic testing for the pathogenic C9ORF72 hexanucleotide expansion in familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
		Review Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time Suzanne B Hendrix Alzheimer's Research & Therapy 2012, 4:24 (13 July 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Suzanne Hendrix reviews the importance of clinical outcomes for validating biomarkers and improving the identification of patients with very early stages of Alzheimer's disease (AD), discussing current neuropsychological tests.

	All
		Commentary Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease Suzanne B Hendrix, Kathleen A Welsh-Bohmer Alzheimer's Research & Therapy 2013, 5:22 (15 May 2013) Abstract \| Full text \| PDF
		Research The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, Dave Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013) Abstract \| Provisional PDF \| PubMed \| Editor’s summary Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
		Review Advances in blood-based protein biomarkers for Alzheimer's disease Lorraine Clark, Thomas Kodadek Alzheimer's Research & Therapy 2013, 5:18 (9 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.
		Review Modeling Alzheimer's disease with non-transgenic rat models Laurent Lecanu, Vassilios Papadopoulos Alzheimer's Research & Therapy 2013, 5:17 (1 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.
		Review Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker, Allan I Levey Alzheimer's Research & Therapy 2013, 5:21 (29 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.
		Review 5-HT₆receptors and Alzheimer's disease María Ramírez Alzheimer's Research & Therapy 2013, 5:15 (22 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT₆ receptor compounds, resulting in 5-HT₆-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).
		Research Neuroprotective effects of D-Ala²GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model Emilie Faivre, Christian Hölscher Alzheimer's Research & Therapy 2013, 5:20 (19 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.
		Research Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models Robyn M Loureiro, Jo Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk, Barbara Tate Alzheimer's Research & Therapy 2013, 5:19 (18 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.
		Review DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease Jyotshna Kanungo Alzheimer's Research & Therapy 2013, 5:13 (8 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jyotshna Kanungo discusses possible mechanisms for the role of DNA-dependent protein kinase (DNA-PK) in neurodegeneration leading to Alzheimer's disease.
		Letter Plasma tau levels in Alzheimer's disease Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansson Alzheimer's Research & Therapy 2013, 5:9 (28 March 2013) Abstract \| Full text \| PDF \| PubMed
		Research The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection Wolfgang W Quitschke, Nicole Steinhauff, Jean Rooney Alzheimer's Research & Therapy 2013, 5:16 (28 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Biweekly intravenous curcuminoid injections at high concentration reduced the plaque load in transgenic Alzheimer's mice to 70% of the control value, but are rapidly metabolised to undetectable levels within 20 minutes.
		Debate Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease? Harald Hampel, Simone Lista Alzheimer's Research & Therapy 2013, 5:11 (18 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Have we learnt all we need to know from genetic studies in Alzheimer's disease (AD)? Harald Hampel and Simone Lista argue that genetics is not over in AD research, in fact it is more at the beginning than at the end.
		Review Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Jon B Toledo, Leslie M Shaw, John Q Trojanowski Alzheimer's Research & Therapy 2013, 5:8 (8 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Toledo, Shaw and Trojanowski review cross-sectional and longitudinal studies of plasma Aβ as a blood-based biomarker for Alzheimer's disease (AD), discussing its potential as a cost effective and non-invasive diagnostic tool.
		Review Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems Douglas Galasko, Todd E Golde Alzheimer's Research & Therapy 2013, 5:10 (7 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Editors-in-Chief Douglas Galasko and Todd Golde introduce a new special series on Peripheral Biomarkers by providing an overview of key concepts relating to Alzheimer’s disease (AD) plasma, serum and blood biomarker studies.
		Research Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth, Alan J Lerner, The Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2013, 5:14 (6 March 2013) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Conversion rates of mild cognitive impairment patients at high risk for progression to Alzheimer's disease (AD) were identified using a novel statistical method based on partially ordered set (poset) models.
		Research Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell, Randi Fain Alzheimer's Research & Therapy 2013, 5:12 (21 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Donepezil 23 mg/day provides significant benefits over 10 mg/day across a range of cognitive domains in patients with moderate to severe Alzheimer's disease, especially in the language domain.
		Editorial The C9ORF72 mutation brings more answers and more questions Bruce L Miller Alzheimer's Research & Therapy 2013, 5:7 (18 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Bruce Miller, Guest Editor of the special series: The new FTD mutation on chromosome 9, discusses the C9ORF72 mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.
		Meeting report Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery Rachel F Lane, Penny A Dacks, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2013, 5:5 (4 February 2013) Abstract \| Full text \| PDF \| PubMed
		Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
		Research Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
		Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
		Review Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss, Sandra E Black Alzheimer's Research & Therapy 2013, 5:1 (9 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lam and colleagues review the different subtypes of Alzheimer's disease (AD), discussing the need for personalized AD medicine and the potential for targeting specific AD subtypes in future clinical trials.
		Research Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application Carina Wattmo, Erik Jedenius, Kaj Blennow, Åsa K Wallin Alzheimer's Research & Therapy 2013, 5:2 (3 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary High compliance to treatment with cholinesterase inhibitor galantamine was seen in a clinical study of patients with Alzheimer's disease (AD), with plasma concentration correlating strongly to dosage.
		Commentary Assessment of psychiatric changes in C9ORF72 frontotemporal dementia Michael Hornberger Alzheimer's Research & Therapy 2012, 4:49 (24 December 2012) Abstract \| Full text \| PDF \| PubMed
		Review Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? Amanda N Sacino, Benoit I Giasson Alzheimer's Research & Therapy 2012, 4:48 (17 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Sacino and Giasson review evidence that a self-promoting prion-like mechanism may contribute to the spread and progression of alpha-synuclein pathology in Parkinson’s disease and other synucleinopathies, calling for further study.
		Research Plasma lipoprotein-associated phospholipase A₂activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study Julie E Davidson, Andrew Lockhart, Leslie Amos, Heide A Stirnadel-Farrant, Vincent Mooser, Marc Sollberger, Axel Regeniter, Andreas U Monsch, Michael C Irizarry Alzheimer's Research & Therapy 2012, 4:51 (7 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Levels of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) did not correlate with cerebrospinal fluid biomarkers such as Abeta and Tau in Alzheimer's disease patients in a cross-sectional study.
		Review NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease Walter J Lukiw Alzheimer's Research & Therapy 2012, 4:47 (6 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Walter Lukiw reviews how epigenetic factors, including NF-kappaB-regulated proinflammatory miRNAs, show an increased abundance in Alzheimer disease (AD) brains and discusses the potential therapeutic applications of miRNA inhibitors.
		Review Treatment implications of C9ORF72 Sharon J Sha, Adam Boxer Alzheimer's Research & Therapy 2012, 4:46 (27 November 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Sha and Boxer discuss the animal models and research tools needed to understand the clinical phenotypes of frontotemporal dementia and amyotrophic lateral sclerosis linked to chromosome 9 (c9FTD/ALS) in C9ORF72-mediated disease.
		Research Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action Patrick D Roberts, Athan Spiros, Hugo Geerts Alzheimer's Research & Therapy 2012, 4:50 (26 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Computational analysis of the pathology and mechanisms of drug action in Alzheimer's disease may improve clinical success rates by addressing the translational gap between preclinical animal models and clinical outcomes.
		Review Neuroimaging features of C9ORF72 expansion Jennifer S Yokoyama, Howard J Rosen Alzheimer's Research & Therapy 2012, 4:45 (16 November 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Yokoyama and Rosen review neuroimaging studies on the pathogenic C9ORF72 expansion; establishing that unique characteristics of C9ORF72-associated disease may aid identification of patients for genetic screening and diagnosis.
		Review Stem cell models of Alzheimer's disease and related neurological disorders Frederick J Livesey Alzheimer's Research & Therapy 2012, 4:44 (6 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Frederick Livesey reviews the feasibility of neuronal stem cell models in Alzheimer's disease (AD), discussing the progress in using this approach to generate useful human models of AD and its future potential.
		Research Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study John M Ringman, Sally A Frautschy, Edmond Teng, Aynun N Begum, Jenny Bardens, Maryam Beigi, Karen H Gylys, Vladimir Badmaev, Dennis D Heath, Liana G Apostolova, Verna Porter, Zeba Vanek, Gad A Marshall, Gerhard Hellemann, Catherine Sugar, Donna L Masterman, Thomas J Montine, Jeffrey L Cummings, Greg M Cole Alzheimer's Research & Therapy 2012, 4:43 (29 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Oral curcumin did not lead to changes in cognitive examinations or plasma biomarker levels in a 24-week randomized, double blind, placebo-controlled study in patients with Alzheimer disease (AD).
		Review Potential sources of interference on Abeta immunoassays in biological samples Hugo Vanderstichele, Erik Stoops, Eugeen Vanmechelen, Andreas Jeromin Alzheimer's Research & Therapy 2012, 4:39 (17 October 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Vanderstichele and colleagues review the importance of assay interferences when diagnosing and measuring therapy responses in Alzheimer's disease (AD); discussing how to make assays more acceptable as in vitro diagnostic biomarker tests.
		Review Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease Leonel T Takada, Sharon J Sha Alzheimer's Research & Therapy 2012, 4:38 (3 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Takada and Sha review the neuropsychiatric features of chromosome 9p-linked frontotemporal dementia (FTD) and the risk that some C9orf72 mutation carriers may be misdiagnosed with primary psychiatric conditions.
		Commentary C9orf72 immunohistochemistry in Alzheimer's disease Tibor Hortobágyi Alzheimer's Research & Therapy 2012, 4:37 (26 September 2012) Abstract \| Full text \| PDF \| PubMed
		Research Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions Colin J Mahoney, Laura E Downey, Gerard R Ridgway, Jon Beck, Shona Clegg, Melanie Blair, Sarah Finnegan, Kelvin K Leung, Tom Yeatman, Hannah Golden, Simon Mead, Jonathan D Rohrer, Nick C Fox, Jason D Warren Alzheimer's Research & Therapy 2012, 4:41 (24 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Longitudinal neuropsychological and neuroimaging data on a cohort of patients with pathological repeat expansions in C9ORF72 is assessed, demonstrating longitudinal biomarkers for tracking the evolution of the C9ORF72 mutation phenotype.
		Commentary Dementia: a global health priority - highlights from an ADI and World Health Organization report Marc Wortmann Alzheimer's Research & Therapy 2012, 4:40 (21 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Marc Wortmann, Executive Director of Alzheimer's Disease International, provides a special commentary explaining the importance of World Alzheimer Reports and the need to create national Alzheimer Plans to provide frameworks for action.
		Commentary Championing of dementia in England Zeinab Abdi, Alistair Burns Alzheimer's Research & Therapy 2012, 4:36 (11 September 2012) Abstract \| Full text \| PDF \| PubMed
		Review Alzheimer's disease diagnostic criteria: practical applications Jeffrey Cummings Alzheimer's Research & Therapy 2012, 4:35 (5 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jeffrey Cummings reviews the advantages and limitations of the IWG and NIA/AA Alzheimer's disease (AD) diagnostic criteria, and discusses improvements for future revisions.
		Review Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease Adam Kline Alzheimer's Research & Therapy 2012, 4:32 (27 August 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Adam Kline discusses therapeutic approaches targeting apolipoprotein E (apoE), the most significant risk factor for non-familial Alzheimer's disease (AD), including key interactions of apoE and amyloid-beta pathology and preclinical animal models.
		Research Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort Sheng Jin, Pau Pastor, Breanna Cooper, Sebastian Cervantes, Bruno A Benitez, Cristina Razquin, Alison Goate, Ibero-American Alzheimer Disease Genetics Group Researchers, Carlos Cruchaga Alzheimer's Research & Therapy 2012, 4:34 (20 August 2012) Abstract \| Full text \| PDF \| PubMed \| F1000 Biology \| Editor’s summary Pooled-DNA sequencing identifies novel GRN and MAPT mutations that match the frequency of APP, PSEN1 and PSEN2 mutations in clinical Alzheimer's disease (AD) cases, suggesting an influence on frontotemporal dementia and AD phenotypes.
		Research Dystrophic neurites express C9orf72 in Alzheimer's disease brains Jun-ichi Satoh, Hiroko Tabunoki, Tsuyoshi Ishida, Yuko Saito, Kunimasa Arima Alzheimer's Research & Therapy 2012, 4:33 (16 August 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary C9orf72 and UBQLN-1 expression in a cluster of dystrophic neurites in senile plaques in Alzheimer's disease brains suggests C9orf72 has a role in the process of neurodegeneration.
		Research Impaired self-other differentiation in frontotemporal dementia due to the C9ORF72 expansion Laura E Downey, Colin J Mahoney, Martin N Rossor, Sebastian J Crutch, Jason D Warren Alzheimer's Research & Therapy 2012, 4:42 (13 August 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
		Debate Con: Alzheimer's disease and circadian dysfunction: chicken or egg? Abhay Moghekar, Richard J O'Brien Alzheimer's Research & Therapy 2012, 4:26 (13 August 2012) Abstract \| Full text \| PDF \| PubMed
		Debate Pro: Alzheimer's disease and circadian dysfunction: chicken or egg? Tracy A Bedrosian, Randy J Nelson Alzheimer's Research & Therapy 2012, 4:25 (13 August 2012) Abstract \| Full text \| PDF \| PubMed
		Research Increased expression of the homologue of enhancer-of-split 1 protects neurons from beta amyloid neurotoxicity and hints at an alternative role for transforming growth factor beta1 as a neuroprotector Pedro J Chacón, Alfredo Rodríguez-Tébar Alzheimer's Research & Therapy 2012, 4:31 (31 July 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Up-regulating the gene Hes1 largely counteracted the effects of amyloid beta (Aβ) on neurons, maintaining GABAergic signaling and preventing cell death; providing strategies for limiting the effects of Alzheimer's disease.
		Review Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia Jennifer C Schymick, Bryan J Traynor Alzheimer's Research & Therapy 2012, 4:30 (26 July 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
		Review Cognitive and behavioral features of c9FTD/ALS Bradley F Boeve, Neill R Graff-Radford Alzheimer's Research & Therapy 2012, 4:29 (20 July 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Boeve and Graff-Radford review the major new findings in familial frontotemporal dementia and/or amyotrophic lateral sclerosis linked to chromosome 9 (c9FTD/ALS) and its recently discovered pathogenic C9ORF72 hexanucleotide expansion.
		Review Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion Jamie C Fong, Anna M Karydas, Jill S Goldman Alzheimer's Research & Therapy 2012, 4:27 (19 July 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Fong and colleagues discuss the genetic counselling considerations for individuals and their families considering genetic testing for the pathogenic C9ORF72 hexanucleotide expansion in familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
		Review Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time Suzanne B Hendrix Alzheimer's Research & Therapy 2012, 4:24 (13 July 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Suzanne Hendrix reviews the importance of clinical outcomes for validating biomarkers and improving the identification of patients with very early stages of Alzheimer's disease (AD), discussing current neuropsychological tests.